Anti-Inflammatory Therapeutics Market (By Drug Class: Anti-inflammatory Biologics, Non-steroidal Anti-inflammatory Drugs, Corticosteroids; By Indication: Arthritis, Respiratory diseases, Multiple sclerosis, Psoriasis, Inflammatory bowel disease, Other inflammatory diseases; By Application: Autoimmune, Inflammatory Diseases, Respiratory Diseases; By Distribution Channel: Hospital Pharmacy, Retail Pharmacy) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Anti-Inflammatory Therapeutics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Anti-Inflammatory Therapeutics Market, by Drug Class, 2024-2033
8.1.1. Anti-inflammatory Biologics
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Corticosteroids
8.1.3.1. Market Revenue and Forecast (2021-2033)
9.1. Anti-Inflammatory Therapeutics Market, by Indication, 2024-2033
9.1.1. Arthritis
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Respiratory diseases
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Multiple sclerosis
9.1.3.1. Market Revenue and Forecast (2021-2033)
9.1.4. Psoriasis
9.1.4.1. Market Revenue and Forecast (2021-2033)
9.1.5. Inflammatory bowel disease
9.1.5.1. Market Revenue and Forecast (2021-2033)
9.1.6. Other inflammatory diseases
9.1.6.1. Market Revenue and Forecast (2021-2033)
10.1. Anti-Inflammatory Therapeutics Market, by Application, 2024-2033
10.1.1. Autoimmune
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Inflammatory Diseases (Rheumatoid Arthritis Psoriasis)
10.1.2.1. Market Revenue and Forecast (2021-2033)
10.1.3. Respiratory Diseases
10.1.3.1. Market Revenue and Forecast (2021-2033)
11.1. Anti-Inflammatory Therapeutics Market, by Distribution Channel, 2024-2033
11.1.1. Hospital Pharmacy
11.1.1.1. Market Revenue and Forecast (2021-2033)
11.1.2. Retail Pharmacy
11.1.2.1. Market Revenue and Forecast (2021-2033)
12.1. North America
12.1.1. Market Revenue and Forecast, by Drug Class (2021-2033)
12.1.2. Market Revenue and Forecast, by Indication (2021-2033)
12.1.3. Market Revenue and Forecast, by Application (2021-2033)
12.1.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Drug Class (2021-2033)
12.1.5.2. Market Revenue and Forecast, by Indication (2021-2033)
12.1.5.3. Market Revenue and Forecast, by Application (2021-2033)
12.1.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Drug Class (2021-2033)
12.1.6.2. Market Revenue and Forecast, by Indication (2021-2033)
12.1.6.3. Market Revenue and Forecast, by Application (2021-2033)
12.1.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Drug Class (2021-2033)
12.2.2. Market Revenue and Forecast, by Indication (2021-2033)
12.2.3. Market Revenue and Forecast, by Application (2021-2033)
12.2.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Drug Class (2021-2033)
12.2.5.2. Market Revenue and Forecast, by Indication (2021-2033)
12.2.5.3. Market Revenue and Forecast, by Application (2021-2033)
12.2.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Drug Class (2021-2033)
12.2.6.2. Market Revenue and Forecast, by Indication (2021-2033)
12.2.6.3. Market Revenue and Forecast, by Application (2021-2033)
12.2.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Drug Class (2021-2033)
12.2.7.2. Market Revenue and Forecast, by Indication (2021-2033)
12.2.7.3. Market Revenue and Forecast, by Application (2021-2033)
12.2.7.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Drug Class (2021-2033)
12.2.8.2. Market Revenue and Forecast, by Indication (2021-2033)
12.2.8.3. Market Revenue and Forecast, by Application (2021-2033)
12.2.8.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Drug Class (2021-2033)
12.3.2. Market Revenue and Forecast, by Indication (2021-2033)
12.3.3. Market Revenue and Forecast, by Application (2021-2033)
12.3.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Drug Class (2021-2033)
12.3.5.2. Market Revenue and Forecast, by Indication (2021-2033)
12.3.5.3. Market Revenue and Forecast, by Application (2021-2033)
12.3.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Drug Class (2021-2033)
12.3.6.2. Market Revenue and Forecast, by Indication (2021-2033)
12.3.6.3. Market Revenue and Forecast, by Application (2021-2033)
12.3.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Drug Class (2021-2033)
12.3.7.2. Market Revenue and Forecast, by Indication (2021-2033)
12.3.7.3. Market Revenue and Forecast, by Application (2021-2033)
12.3.7.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Drug Class (2021-2033)
12.3.8.2. Market Revenue and Forecast, by Indication (2021-2033)
12.3.8.3. Market Revenue and Forecast, by Application (2021-2033)
12.3.8.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Drug Class (2021-2033)
12.4.2. Market Revenue and Forecast, by Indication (2021-2033)
12.4.3. Market Revenue and Forecast, by Application (2021-2033)
12.4.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Drug Class (2021-2033)
12.4.5.2. Market Revenue and Forecast, by Indication (2021-2033)
12.4.5.3. Market Revenue and Forecast, by Application (2021-2033)
12.4.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Drug Class (2021-2033)
12.4.6.2. Market Revenue and Forecast, by Indication (2021-2033)
12.4.6.3. Market Revenue and Forecast, by Application (2021-2033)
12.4.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Drug Class (2021-2033)
12.4.7.2. Market Revenue and Forecast, by Indication (2021-2033)
12.4.7.3. Market Revenue and Forecast, by Application (2021-2033)
12.4.7.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Drug Class (2021-2033)
12.4.8.2. Market Revenue and Forecast, by Indication (2021-2033)
12.4.8.3. Market Revenue and Forecast, by Application (2021-2033)
12.4.8.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Drug Class (2021-2033)
12.5.2. Market Revenue and Forecast, by Indication (2021-2033)
12.5.3. Market Revenue and Forecast, by Application (2021-2033)
12.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Drug Class (2021-2033)
12.5.5.2. Market Revenue and Forecast, by Indication (2021-2033)
12.5.5.3. Market Revenue and Forecast, by Application (2021-2033)
12.5.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Drug Class (2021-2033)
12.5.6.2. Market Revenue and Forecast, by Indication (2021-2033)
12.5.6.3. Market Revenue and Forecast, by Application (2021-2033)
12.5.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)
13.1. Eli Lily and Company
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. AstraZeneca PLC
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Amgen Inc.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. F. Hoffman
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Abbvie, Inc.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Johnson & Johnson
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. GlaxoSmithKline
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Merck & CO., Inc.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Novartis
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Pfizer, Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample